Avacta Group (LON:AVCT) Reaches New 1-Year High – Time to Buy?

Avacta Group Plc (LON:AVCT)’s share price reached a new 52-week high during trading on Friday . The stock traded as high as GBX 85 and last traded at GBX 82.50, with a volume of 8607747 shares changing hands. The stock had previously closed at GBX 81.

Avacta Group Stock Performance

The firm has a market capitalization of £374.14 million, a PE ratio of -4.70 and a beta of 1.12. The firm’s fifty day moving average price is GBX 69.72 and its 200 day moving average price is GBX 66.83. The company has a current ratio of 0.79, a quick ratio of 4.96 and a debt-to-equity ratio of 14,168.75.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).